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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To compare visual outcomes after penetrating keratoplasty and DALK for keratoconus and identify the factors contributing to poor
outcomes.
1Penetrating keratoplasty versus deep anterior lamellar keratoplasty for treating keratoconus (Protocol)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Archived at Flinders University: dspace.flinders.edu.au
B A C K G R O U N D
Description of the condition
Keratoconus is an ectatic (weakening) disease of the cornea, which
is the clear surface at the very front of the eye (Coster 2002).
Weakness in the tensile strength of the cornea results in distortion
of the anterior refractive surface of the eye. Theweakened cornea is
unable to stand the intraocular pressure and protrudes in a conical
shape (Ertan2008a). The increased curvature of the conical cornea
results in myopia (short-sightedness) and irregularities of the cone
produce astigmatism, which causes blurred vision.
Keratoconus is common. It is usually bilateral and manifests early,
in the first two decades of life (Ertan 2008a; Espandar 2010). Pro-
gression is uncommon after the age of 35 years (Romero-Jimenez
2010). For most people, progression is slow. Early onset of the
condition is often associated with more rapid progression.
Corneal curvature is used to assess the severity and progression of
keratoconus. Central corneal curvature is adequately measured by
keratometry. More extensive assessment of corneal shape requires
videokeratography (Gobbe 2005; Jafri 2007).
Various systems have been developed to classify the progression of
keratoconus into different stages of the disease (Romero-Jimenez
2010). One such system which is widely accepted and utilised is
the Amsler-Krumeich classification system, separating the disease
into four stages based on level of myopia and astigmatism, cen-
tral keratometric readings, scarring and corneal thickness (Ertan
2008b). A variation on this system has been developed more re-
cently by Alió and Shabayek (Alió 2006) to incorporate diagnostic
information relating to the severity of higher order corneal aberra-
tions, the visual distortion created by a wavefront of light passing
through an irregular eye.
Advanced keratoconus is also accompanied by an increased in-
cidence of hydrops. This is an acute stromal oedema caused by
breaks in Descemet’s membrane through which aqueous humour,
the substance filling the space between the lens and cornea, en-
ters and swells the stroma, the major component of the cornea.
Hydrops generally results in scarring of the cornea, which can
have a continued impact on visual potential (Rabinowitz 1998;
Romero-Jimenez 2010), however it is a rare complication (Bilgin
2009).
Keratoconus has been reported to affect approximately one person
in 2000 in the North American population (Rabinowitz 1998).
Although some suggest that the prevalence could actually be as
high as one per 500 people (Ertan 2008a; Espandar 2010), other
studies have found lower prevalence rates, sometimes as small as
one per 70,000 people. These studies were conducted in a num-
ber of different countries and though the disease affects all ethnic
groups findings suggest that people of various ethnic backgrounds,
particularly those of Asian descent, may be more prone to the dis-
ease than Caucasian populations (Georgiou 2004). The inconsis-
tency in reported prevalence across studies is probably also due
to the wide range of definitions and diagnostic criteria utilised by
practitioners and researchers (Rabinowitz 1998; Romero-Jimenez
2010).
The disease affects both men and women however some studies
have found variations in prevalence across the sexes. Genetics have
been found to play a role in the disease, with a family history
reported in approximately 6% to 10% of cases and an increased
risk in first degree relatives also documented. The definitive cause
of keratoconus is still unknown (Rabinowitz 1998; Wang 2000).
Description of the intervention
The treatment of keratoconus relies on the use of a hard or semi-
rigid contact lens to cover the irregular cornea and provide a
new, appropriately curved anterior refractive surface (Bilgin 2009;
Rabinowitz 1998). If the surface of the conical cornea is too steep
or too irregular to bear a contact lens, or if the eye is too sensitive
to tolerate a lens, surgery becomes necessary. Approximately 10%
to 15% of patients diagnosed with keratoconus require surgery
(Rabinowitz 1998; Romero-Jimenez 2010). Corneal transplanta-
tion is the procedure employed. The purpose of corneal transplan-
tation for keratoconus is to replace the abnormal anterior refract-
ing surface of the eye with a donor cornea that has a normal an-
terior surface shape. Corneal transplantation for keratoconus may
be full-thickness (penetrating) or partial-thickness (lamellar).
Penetrating keratoplasty
Penetrating keratoplasty has been performed as a treatment for
keratoconus for over 70 years (Castroviejo 1948) and remains the
leading treatment for those sufferers with contact lens intolerance
(Jhanji 2010; Rabinowitz 1998). Existing longitudinal data show
that keratoconus is one of the most common indications for pene-
trating keratoplasty and that these recipients have higher graft sur-
vival rates (Jaycock 2008; Williams 2007). An analysis conducted
in 2006 concluded that it was a cost-effective treatment for severe
cases of keratoconus (Roe 2008).
Penetrating keratoplasty involves the replacement of a full-thick-
ness portion of the cornea (Coster 2002; Romero-Jimenez 2010).
There are many variations in technique, however a recent review
of the published evidence concluded that there was “no evidence
for the superiority of any specific technique” (Frost 2006).
Deep anterior lamellar keratoplasty
More recently, lamellar transplantation, in which only a partial-
thickness of the cornea is replaced, has been reintroduced as a
surgical treatment for keratoconus (Romero-Jimenez 2010). This
form of transplantation has been used for decades, however poor
visual outcomes resulted in a decline in its use (Trimarchi 2001).
Newer techniques in which the interface of the donor and host is
at the level of Descemet’s membrane have reinvigorated the use of
this form of surgery (Karimian 2010; Sugita 1997).
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Deep anterior lamellar keratoplasty (DALK) is frequently used for
keratoconus. Advocates claim that this procedure is preferable to
penetrating keratoplasty for eyes that are free from corneal scarring
or hydrops (Jhanji 2010). The premise is that, because the en-
dothelial cell layer of the recipient is left intact during DALK, the
prospect of endothelial rejection is precluded (Romero-Jimenez
2010; Tan 2010).
Various techniques have been used to dissect the stroma from
the underlying Descemet’s membrane (Jhanji 2010; Tan 2010).
Common approaches include manual dissection (Anwar 2002;
Karimian 2010), which may be enhanced by injection of air into
the anterior chamber and stroma (Archila 1984); dissection with
a visco-elastic substance, as advocated by Melles (Melles 2000);
or the big-bubble dissection technique advocated by Anwar et al
(Anwar 2002). Each approach has its proponents.
How the intervention might work
To reiterate, the purpose of corneal transplantation for keratoconus
is to replace the abnormal anterior refractive surface of the eye with
a cornea that has a normal shape. In penetrating keratoplasty the
full-thickness of the cornea is replaced, while in DALK the corneal
stroma is replaced down to theDescemet’smembrane. The benefit
and risk profile of the two procedures may be different, however
the desired therapeutic outcomes are identical.
Why it is important to do this review
Although the aim of the procedures is the same, the risk profiles
may be different and disparate outcomes have been reported. It
is important that outcomes from the newer treatment, DALK,
be compared to those achieved using the traditional penetrating
technique in terms of visual outcome and graft survival. The results
will help to inform corneal surgeons and keratoconus sufferers
of the appropriateness of each treatment for this condition. This
will aid in the clinical decision making process with regard to the
selection of treatment for individuals with this condition.
O B J E C T I V E S
To compare visual outcomes after penetrating keratoplasty and
DALK for keratoconus and identify the factors contributing to
poor outcomes.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Wewill include randomised controlled trials (RCTs) that meet the
stated inclusion criteria. The review will include all RCTs in which
one arm received treatment with penetrating keratoplasty and the
other with DALK. Details of the randomisation procedure must
be available.Where a study is defined as being randomised but the
details are not included in the published literature, we will attempt
to gain this information from the authors. If details of the method
of randomisation cannot be obtained we will retain the study in
the review, acknowledging its unclear risk of bias, but exclude it
from any meta-analyses.
Types of participants
Participants of any age may be included in selected trials. We will
exclude studies that included participants with other confounding
related disorders, such as pellucid marginal degeneration (PMD)
(the thinning of the periphery rather than the central area of the
cornea) or keratoglobus in which the entire corneal surface is in-
volved. We will only include in the review studies which specify a
reliable method of diagnosis of the keratoconus (slit lamp exami-
nation, corneal topography, wave front analysis). Participants may
be at any stage of the disease and there may be a mixture of stages
of progression amongst participants as long as this is specified. Par-
ticipants must not have a history of corneal scarring or hydrops as
this would preventDALK frombeing a suitable treatment for their
condition. With regards to keratoconus prevalence or progression,
no significant differences across cultural and racial backgrounds
have been confirmed in the scientific literature. Thus, studies from
anywhere in the world will be eligible for inclusion.
Types of interventions
We will include trials in which the outcomes of penetrating ker-
atoplasty and DALK, as treatments for keratoconus, were directly
compared to one another. We will also include studies in which
both treatments were compared to one another as well as a third
treatment or a control group. We will exclude studies comparing
either one of these treatments alone to a third treatment or a con-
trol group.
Types of outcome measures
Studies which report at least one clinical outcome will be eligible
for inclusion.
Primary outcomes
The vast majority of keratoconus patients who undergo corneal
graft surgery do so in order to gain improved vision (Williams
2007). In some cases, uncorrected post-graft visionmay improve to
a functional level but for others, approximately half of recipients,
correction with contact lenses or spectacles will still be necessary in
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order to achieve optimal, useful vision. Therefore, wewill use post-
graft best corrected visual acuity (BCVA) as the primary outcome
measure.
BCVA should be provided (mean and range) in terms of either
Snellen or LogMARmeasurements (measurements given in either
of these two forms can be easily converted into the other for the
relevant analyses). Where necessary, Snellen measurements will be
converted intoLogMAR, not LogMARasmeasured on anETDRS
chart. Post-graft BCVA should be measured at three months after
surgery. Post-graft BCVA will be considered in two ways, firstly
in terms of the level of BCVA achieved (6/12 or better versus 6/
15 or worse) and also in terms of change from pre-graft BCVA
(difference in lines of Snellen acuity), where recorded.
Secondary outcomes
BCVA at sixmonths, 12months and 24monthswill be analysed as
secondary outcomes. Further measures of refraction will be anal-
ysed. Uncorrected visual acuity (UCVA) will be a secondary out-
come measure. Again, this will be analysed for measurements at
three, six, 12 and 24 months post-surgery and should be provided
(mean and range) in terms of either Snellen or LogMAR mea-
surements. As with BCVA, these data will be considered both in
terms of the final UCVA achieved and with regards to the change
in UCVA pre to post-graft. We will also consider method of vi-
sual correction (in order to be able to achieve a desirable BCVA)
and keratometry readings (to determine level of astigmatism) as
secondary outcome measures.
Other secondary outcome measures will be the frequency of rejec-
tion episodes and graft failure.
Timing of outcome assessment
As visual recovery from corneal grafting can continue for a long
time, outcomemeasures will be analysed primarily at threemonths
post-graft; as well as in the context of secondary outcomemeasures
at the following periods of time post-graft, where possible: six, 12
and 24months. In addition, the removal of sutures has been shown
to impact on final visual acuity and so, if practical, comparisons
will be made between both BCVA and UCVA before and after
suture removal.
Adverse outcomes
Other adverse effects may be reported, including intraoperative
complications like perforation or need for rebubbling, and post-
operative events such as scarring, infection, cataract or pain. We
will also compare these across treatment groups.
Search methods for identification of studies
Electronic searches
We will search the Cochrane Central Register of Controlled Tri-
als (CENTRAL) (which contains the Cochrane Eyes and Vision
Group Trials Register), the Database of Abstracts of Reviews of
Effects (DARE) (The Cochrane Library), MEDLINE, PubMed,
EMBASE, Latin American and Caribbean Health Sciences Lit-
erature Database (LILACS), Cumulative Index to Nursing and
Allied Health Literature (CINAHL), OpenGrey, Web of Science
- Science Citation Index (SCI), Health Collection - Informit,
the metaRegister of Controlled Trials (mRCT) (www.controlled-
trials.com), ClinicalTrials.gov (www.clinicaltrials.gov) and the
WHO International Clinical Trials Registry Platform (ICTRP) (
www.who.int/ictrp/search/en). There will be no date or language
restrictions in the electronic searches for trials.
See: Appendices for details of search strategies for CENTRAL
and DARE (Appendix 1), MEDLINE (Appendix 2), PubMed
(Appendix 3), EMBASE (Appendix 4), LILACS (Appendix 5),
CINAHL (Appendix 5), OpenGrey (Appendix 7), SCI (Appendix
8), Informit (Appendix 9), mRCT (Appendix 10), ClinicalTri-
als.gov (Appendix 11) and the ICTRP (Appendix 12).
Searching other resources
We will handsearch the following international conference pro-
ceedings from 1999 onwards in order to identify further, unpub-
lished studies.
1. American Society of Cataract and Refractive Surgery Sympo-
sium and Congress
2. Asia Pacific Academy of Ophthalmology Congress
3. Cambridge Ophthalmological Society Meeting
4. European Society of Cataract andRefractive SurgeonsCongress
5. International Congress of Eye Research
6. Royal Australian and New Zealand College of Ophthalmology
Congress
7. Royal College of Ophthalmologists Congress
8. World Cornea Congress
9. World Ophthalmology Congress
We will contact the authors of any studies identified in this way
to gain further information where this is required. We will also
handsearch the reference lists of selected studies in order to identify
other relevant articles, conference presentations or book chapters.
Data collection and analysis
Selection of studies
The two authors will independently assess all citations gathered us-
ing the outlined parameters. The authors will classify each citation
as either ’definitely not relevant’ or ’potentially relevant’. Where a
study is judged by both authors at this time to be ’definitely not
relevant’, it will be excluded from further analysis. In cases where
one author believes a study to be ’definitely not relevant’ while the
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other classifies it as ’potentially relevant’ the final classification of
the study will be determined by consensus or, if the two authors
cannot reach an agreement, by reference to a third author.
Where citations were classified as ’potentially relevant’, full copies
of related studies will be obtained and assigned an identification
number (ID). Where a study published in a language other than
English is identified as being potentially relevant, we will initially
arrange translation of themethods and results sections of the study.
If they appear to meet the selection criteria, we will then seek a full
English translation of the study. Where the published data are felt
by at least one author to be insufficient to determine the relevance
of the study, trial investigators will be contacted to request the
necessary information.
Having read the full articles and considered any further informa-
tion gathered from trial investigators, the two authors will classify
them as either ’relevant’ or ’not relevant’. The lists of both authors
will be compared. Those that are classified as ’not relevant’ by
both authors will be excluded at this point from the review. We
will record the reasons for their exclusion and these will be docu-
mented in the review. Those that are classified as ’relevant’ by both
authors will be included in the review. Those that are classified as
’relevant’ by one author and ’not relevant’ by the other will be fur-
ther discussed by the two authors and a decision made regarding
their inclusion. If, for any studies requiring further discussion, the
two authors cannot reach agreement on classification, consensus
will be obtained by reference to a third author. The reasons for any
further exclusions will be recorded and documented in the review.
The data will be entered into RevMan (Review Manager 2011) at
each step in the review process.
Data extraction and management
The two authors will independently extract the data using a form
developed by the Cochrane Eyes and Vision Group. This will
include information on the following.
1. The age, gender, race, geographical location and grade of ker-
atoconus of the participants, as well as the number in each treat-
ment group and the comparability of the two groups on the afore-
mentioned parameters at baseline.
2. The methods used in each intervention group.
3. Information onmissing data and participants who did not com-
plete the trial.
4. The outcomes of the treatments. Dichotomous data will be
collected in terms of number at risk and number of events, while
means and standard deviations will be used for continuous data,
or medians and interquartile ranges for skewed continuous data.
Data will be extracted for the outcome measures outlined for this
review.
One of the authors will enter the data into RevMan (Review
Manager 2011), with the second author checking the entered data
for inconsistencies or errors. Any disagreement will be resolved by
discussion amongst the two authors, or with reference to a third
author if no consensus can be reached.Where there ismissing data,
this will be identified, along with any reasons given, and analysis
will be conducted utilising the available data.
Assessment of risk of bias in included studies
The two authors will independently assess the risk of bias for the
included studies as per the methods given in Chapter 8 of the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011). Methodological quality will be assessed for the following
parameters.
Potential issues relating to selection bias
1. Inclusion and exclusion criteria.
2. Method of keratoconus grading (slit lamp examination, corneal
topography, wave front analysis or combination).
3. Randomisation technique: randomisation via a random num-
ber generator, random number table, shuffled cards or shuffled
envelopes, where the assignment of treatment groups is conducted
and confirmed prior to specific patient allocation and cannot be
changed after this point, will be considered appropriate. Inade-
quate techniques will include alternation, assignment based on
variables such as record numbers, dates of birth or days of the
week, or any form of randomisation in which participant assign-
ment could be altered or affected by the treating surgeon after the
initial assignment. Studies with inadequate randomisation tech-
niques will be excluded and the reasons for this recorded.
4. Equality of comparison groups.
Potential issues relating to performance bias
5. Allocation concealment: as the two techniques differ, the
providers cannot be masked however the recipients and those ad-
ministering the assessments of outcomes should ideally be.
Potential issues relating to detection bias
6. Outcome measurements: despite differences in the techniques,
outcomes of the interventions should be measured in the same
way for both.
Potential issues relating to attrition bias
7. Completion of follow-up: was this equal across treatment
groups, what were the reasons for this and were there adequate
numbers remaining for the results to be meaningful?
Each author will grade the studies on each of these six parameters,
providing a determination of A (low risk of bias), B (unclear risk of
bias), or C (high risk of bias). The review authors will discuss any
disagreements in classification. If necessary, the authors of the trials
in question will be contacted to clarify any unclear information.
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Measures of treatment effect
Outcome measures will comprise two types of data: continuous
and dichotomous. Weighted mean differences will be used to an-
alyze continuous data (BCVA and UCVA measured in LogMAR,
as well as change in BCVA and UCVALogMAR results) where the
data is normally distributed. Where BCVA and UCVA are pro-
vided in terms of Snellen acuity, these figures will be transformed
into LogMAR measurements for the purposes of these analyses.
Where continuous data are not normally distributed, they will be
dichotomised for analysis. For outcomes with dichotomous data
(functional level of BCVA or UCVA, contact lens tolerance, rejec-
tion episodes, graft failure, occurrence of other adverse events) we
will measure the effect size using the odds ratio (OR).
Unit of analysis issues
All unit of analysis issues will be dealt with in the manner specified
in Chapter 9 of the Cochrane Handbook for Systematic Reviews of
Interventions (Deeks2011). As keratoconus is a bilateral condition,
it is possible that some trials will involve one eye of each patient to
be assigned to one treatment group (penetrating keratoplasty or
DALK) and the other to the other treatment group and then the
overall outcomes compared. Providing that adequate randomisa-
tion occurred in terms of which eye was assigned to which treat-
ment group, the analysis allowed for clustering by patient and all
patients had both eyes included in the study, such studies would
still meet the criteria for the review as these surgeries will be per-
formed at different times. These trials will still be included in the
analysis, with attention paid to this issue during sensitivity analy-
sis.
It is also possible that some studies may enter all eyes meeting
the inclusion criteria into the study (including multiple eyes of
one patient) and then randomise all of the eyes to a treatment
group. This would mean that the same treatment may be received
in both eyes of the same patient, or that some patients may have
both eyes included in the trial while others have just one. Because
of the potential inconsistent within-person clustering inherent in
this design, such trials will be excluded from meta-analyses.
Dealing with missing data
Should any studies have missing data, the cases lost to follow-up
will be documented and available case analysis reported. No miss-
ing data will be imputed. We will consider the potential impact
of any missing data. Where large amounts of data are missing, we
will conduct intention-to-treat (ITT) analyses, where possible, to
determine if this has had a significant impact on the results. If it
is determined that it did have, the study will be excluded from
further analyses.
Assessment of heterogeneity
The heterogeneity of the included studies will be assessed in order
to determine whether it is appropriate to carry out a meta-analysis
on the data. This will be done by examining the characteristics of
the studies and the forest plot of study results, and by conducting a
Chi² test of statistical heterogeneity andusing this to determine the
I² statistic. If the I² statistic indicates under 30% variability due to
heterogeneity, this will be considered to be non-significant, while
over 50% will be considered to indicate significant heterogeneity.
For cases in which 30% to 50% heterogeneity is estimated, the
magnitude and direction of the effect as well as the P value of
the Chi² test and confidence interval of the I² statistic will be
considered when making a final decision about the significance.
If heterogeneity of the studies is determined to be significant,
the results will not be combined in a meta-analysis but rather
reported in a descriptive summary. If significant heterogeneity is
not present, a meta-analysis will be conducted using the random-
effects model or, if only a small number of studies are included,
the fixed-effect model.
Assessment of reporting biases
In order to assess reporting bias the intended outcome measures
for each included trial, as recorded in either the trial protocol or the
methods sections of resulting articles, will be compared to those
reported in the results sections of subsequent reports and articles.
In addition, a funnel plot and sensitivity analysis will be used to
assess reporting bias.
Data synthesis
Where meta-analyses are deemed appropriate, summary measures
will be calculated using the random-effects model if four or more
RCTs are identified, or using the fixed-effect model if two or three
studies are identified. If meta-analyses are not judged to be appro-
priate, results will be provided in a descriptive summary form.
Subgroup analysis and investigation of heterogeneity
If heterogeneity of the studies is determined to be significant,
the results may not be combined in a meta-analysis but rather
reported in a descriptive summary. Where reported in the same
trials, subgroup analyseswill be conducted for the twomainDALK
surgical techniques: the big-bubble and theMalles. These analyses
will determine whether the heterogeneity of the overall review is
affected by the differences between these two techniques.
Sensitivity analysis
The initial analysis conducted will include all trials which met
the inclusion criteria. Analyses will then be re-run on the data
in which: 1) any trials for which the risk of allocation bias was
judged to be high are removed, 2) any trials for which the risk on
any parameter was judged to be high are removed, 3) any trials
that were funded by industry are removed, and 4) trials which
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are unpublished are removed. In this way, it will be possible to
assess how strongly the results of our review are related to the
decisions and assumptions that we have made throughout the
review process. In addition, if any trials are included in which
each patient receives each intervention (one in each eye) and the
outcomes are compared, these will be removed to check that this
clustering of participants does not have a significant impact on the
results.
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A P P E N D I C E S
Appendix 1. CENTRAL and DARE search strategy
#1 MeSH descriptor Keratoconus
#2 keratocon*
#3 ectatic* or ectasia
#4 (#1 OR #2 OR #3)
#5 MeSH descriptor Keratoplasty, Penetrating
#6 (penetrating or perforating) near/2 (keratoplast*)
#7 full near/3 thickness near/3 cornea*
#8 (#5 OR #6 OR #7)
#9 deep anterior lamellar keratoplast*
#10 deep lamellar keratoplast*
#11 partial near/3 thickness near/3 cornea*
#12 big near/2 bubble
#13 DALK
#14 (#9 OR #10 OR #11 OR #12 OR #13)
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#15 (#4 AND #8 AND #13)
Appendix 2. MEDLINE (Ovid) search strategy
1. randomized controlled trial.pt.
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. exp animals/
10. exp humans/
11. 9 not (9 and 10)
12. 8 not 11
13. exp Keratoconus/
14. keratocon$.tw.
15. (ectatic$ or ectasia).tw.
16. or/13-15
17. Keratoplasty, Penetrating/
18. ((penetrating or perforating) adj2 keratoplast$).tw.
19. (full adj3 thickness adj3 cornea$).tw.
20. or/17-19
21. deep anterior lamellar keratoplast$.tw.
22. deep lamellar keratoplast$.tw.
23. (partial adj3 thickness adj3 cornea$).tw.
24. (big adj2 bubble).tw.
25. DALK.tw.
26. or/21-25
27. 16 and 20 and 26
28. 12 and 27
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville et al (Glanville 2006).
Appendix 3. PubMed search strategy
(((randomized controlled trial[pt] OR controlled clinical trial[pt]) OR (randomized OR randomised OR randomly OR placebo[tiab])
OR (trial[ti]) OR (“Clinical Trials as Topic”[MeSH Major Topic])) NOT ((“Animals”[Mesh]) NOT (“Humans”[Mesh] AND “An-
imals”[Mesh]))) AND (((keratoconus[MeSH Terms]) OR (keratocon*) OR (ectatic* OR ectasia)) AND ((keratoplasty, penetrat-
ing[MeSH Terms]) OR (keratoplast*) OR (DALK)))
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Appendix 4. EMBASE (Ovid) search strategy
1. exp randomized controlled trial/
2. exp randomization/
3. exp double blind procedure/
4. exp single blind procedure/
5. random$.tw.
6. or/1-5
7. (animal or animal experiment).sh.
8. human.sh.
9. 7 and 8
10. 7 not 9
11. 6 not 10
12. exp clinical trial/
13. (clin$ adj3 trial$).tw.
14. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
15. exp placebo/
16. placebo$.tw.
17. random$.tw.
18. exp experimental design/
19. exp crossover procedure/
20. exp control group/
21. exp latin square design/
22. or/12-21
23. 22 not 10
24. 23 not 11
25. exp comparative study/
26. exp evaluation/
27. exp prospective study/
28. (control$ or prospectiv$ or volunteer$).tw.
29. or/25-28
30. 29 not 10
31. 30 not (11 or 23)
32. 11 or 24 or 31
33. exp keratoconus/
34. keratocon$.tw.
35. (ectatic$ or ectasia).tw.
36. or/33-35
37. exp penetrating keratoplasty/
38. ((penetrating or perforating) adj2 keratoplast$).tw.
39. (full adj3 thickness adj3 cornea$).tw.
40. or/37-39
41. deep anterior lamellar keratoplast$.tw.
42. deep lamellar keratoplast$.tw.
43. (partial adj3 thickness adj3 cornea$).tw.
44. (big adj2 bubble).tw.
45. DALK.tw.
46. or/41-45
47. 36 and 40 and 46
48. 32 and 47
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Appendix 5. LILACS search strategy
keratocon$ and keratoplast$ or DALK
Appendix 6. CINAHL (EBSCO) search strategy
S7 S3 AND S6
S6 S4 OR S5
S5 DALK
S4 keratoplasty or keratoplasties
S3 S1 OR S2
S2 ectatic or ectasia
S1 Keratoconus
Appendix 7. OpenGrey search strategy
keratoconus and keratoplasty
Appendix 8. Web of Science SCI search strategy
#9 #7 AND #8
#8 TS=random*
#7 #3 AND #6
#6 #4 OR #5
#5 TS=DALK
#4 TS=keratoplasty
#3 #1 OR #2
#2 TS=ectatic
#1 TS=keratoconus
Appendix 9. Health Collection (Informit) search strategy
SUBJECT=(keratoconus) AND SUBJECT=(keratoplasty)
Appendix 10. metaRegister of Controlled Trials search strategy
keratoconus AND keratoplasty
Appendix 11. ClinicalTrials.gov search strategy
Keratoconus AND Keratoplasty
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Appendix 12. ICTRP search strategy
keratoconus AND keratoplasty
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